SARS-CoV-2 infection in patients with primary central nervous system lymphoma.
COVID-19
PCNSL
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
17
09
2020
accepted:
08
11
2020
revised:
26
10
2020
pubmed:
3
1
2021
medline:
14
8
2021
entrez:
2
1
2021
Statut:
ppublish
Résumé
Cancer patients may be at higher risk for severe coronavirus infectious disease-19 (COVID-19); however, the outcome of Primary Central Nervous System Lymphoma (PCNSL) patients with SARS-CoV-2 infection has not been described yet. We conducted a retrospective study within the Lymphomes Oculo-Cérébraux national network (LOC) to assess the clinical characteristics and outcome of SARS-CoV-2 infection in PCNSL patients (positive real-time polymerase chain reaction of nasopharyngeal swab or evocative lung computed tomography scan). We compared clinical characteristics between patients with severe (death and/or intensive care unit admission) and mild disease. Between March and May 2020, 13 PCNSL patients were diagnosed with SARS-CoV-2 infection, 11 (85%) of whom were undergoing chemotherapy at the time of infection. The mortality rate was 23% (3/13), and two additional patients (15%) required mechanical ventilation. Two patients (15%) had no COVID-19 symptoms. History of diabetes mellitus was more common in severe patients (3/5 vs 0/8, p = 0.03). Two patients recovered from COVID-19 after mechanical ventilation during more than two weeks and resumed chemotherapy. In all, chemotherapy was resumed after COVID-19 recovery in nine patients (69%) after a median delay of 16 days (range 3-32), none of whom developed unusual chemotherapy complication nor SARS-Cov2 reactivation. This preliminary analysis suggests that, while being at higher risk be for severe illness, PCNSL patients with COVID-19 might be treated maximally especially if they achieved oncological response at the time of SARS-CoV-2 infection. Chemotherapy might be resumed without prolonged delay in PCNSL patients with COVID-19.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer patients may be at higher risk for severe coronavirus infectious disease-19 (COVID-19); however, the outcome of Primary Central Nervous System Lymphoma (PCNSL) patients with SARS-CoV-2 infection has not been described yet.
METHODS
METHODS
We conducted a retrospective study within the Lymphomes Oculo-Cérébraux national network (LOC) to assess the clinical characteristics and outcome of SARS-CoV-2 infection in PCNSL patients (positive real-time polymerase chain reaction of nasopharyngeal swab or evocative lung computed tomography scan). We compared clinical characteristics between patients with severe (death and/or intensive care unit admission) and mild disease.
RESULTS
RESULTS
Between March and May 2020, 13 PCNSL patients were diagnosed with SARS-CoV-2 infection, 11 (85%) of whom were undergoing chemotherapy at the time of infection. The mortality rate was 23% (3/13), and two additional patients (15%) required mechanical ventilation. Two patients (15%) had no COVID-19 symptoms. History of diabetes mellitus was more common in severe patients (3/5 vs 0/8, p = 0.03). Two patients recovered from COVID-19 after mechanical ventilation during more than two weeks and resumed chemotherapy. In all, chemotherapy was resumed after COVID-19 recovery in nine patients (69%) after a median delay of 16 days (range 3-32), none of whom developed unusual chemotherapy complication nor SARS-Cov2 reactivation.
CONCLUSION
CONCLUSIONS
This preliminary analysis suggests that, while being at higher risk be for severe illness, PCNSL patients with COVID-19 might be treated maximally especially if they achieved oncological response at the time of SARS-CoV-2 infection. Chemotherapy might be resumed without prolonged delay in PCNSL patients with COVID-19.
Identifiants
pubmed: 33387015
doi: 10.1007/s00415-020-10311-w
pii: 10.1007/s00415-020-10311-w
pmc: PMC7776286
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3072-3080Subventions
Organisme : SiRIC CURAMUS Institut National du Cancer
ID : INCa-DGOS-Inserm_12560
Informations de copyright
© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Ann Oncol. 2020 Oct;31(10):1320-1335
pubmed: 32745693
Lancet Infect Dis. 2020 Sep;20(9):1043-1050
pubmed: 32539988
Ann Intern Med. 2020 Jun 2;172(11):756-758
pubmed: 32219410
Crit Care. 2020 May 15;24(1):228
pubmed: 32414403
Curr Oncol Rep. 2020 May 8;22(5):53
pubmed: 32385672
Science. 2020 Jul 10;369(6500):208-211
pubmed: 32404476
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Lancet Oncol. 2020 Apr;21(4):e180
pubmed: 32142622
J Clin Virol. 2020 Jun;127:104354
pubmed: 32305882
Leukemia. 2020 Jun;34(6):1637-1645
pubmed: 32332856
Lancet Haematol. 2020 Oct;7(10):e737-e745
pubmed: 32798473
Br J Haematol. 2020 Jul;190(1):e16-e20
pubmed: 32379921
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Sci Rep. 2020 Jul 24;10(1):12567
pubmed: 32709854
Int J Infect Dis. 2020 May;94:154-155
pubmed: 32179137
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Radiology. 2020 Aug;296(2):E79-E85
pubmed: 32243238
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Clin Oncol. 2005 Aug 1;23(22):5034-43
pubmed: 15955902
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
J Hematol Oncol. 2020 Jun 10;13(1):75
pubmed: 32522278
Emerg Infect Dis. 2020 Aug;26(8):1666-1670
pubmed: 32324530
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):395-403
pubmed: 32334395
J Assoc Med Microbiol Infect Dis Can. 2020 Dec 31;5(4):223-234
pubmed: 36340059
J Infect. 2020 May;80(5):e1-e6
pubmed: 32171869
N Engl J Med. 2020 Apr 9;382(15):1476-1478
pubmed: 32163698
AJR Am J Roentgenol. 2020 Jul;215(1):87-93
pubmed: 32174129
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930